Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovasc...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

Lskynrd1 Mar. 15 at 7:11 PM

$ESPR Skipper and DJ both leaving at the same time is concerning. They were both 2 of the biggest BempA supporters and both in for big money then suddenly gone during a daily sell-off, idk thoughts?

0 · Reply

GrandMasterApe Mar. 15 at 5:31 PM

$ESPR What happened to DJ? He deleted his account? Anyone know if he’s okay?

2 · Reply

Rong0722 Mar. 15 at 4:46 PM

$ESPR

0 · Reply

Albertowest Mar. 15 at 4:05 PM

$ESPR https://www.expo.acc.org/ACC26/Public/eventmap.aspx?shavailable=1&shExhlist=1 In Harlow We Trust 🫶🏻

0 · Reply

Petey3163 Mar. 15 at 12:35 PM

$ESPR do we think there will be a US partner now or with the acquisition they are definitely signaling we are going solo? Are there still any hopes of a BO?

1 · Reply

Blocktatch Mar. 15 at 11:07 AM

$ESPR What do you think of Merck's drug? Could it be a problem for Esperion in the long term? From what I understand, it could be less preferred than BA for several reasons.

1 · Reply

Moneo Mar. 15 at 10:52 AM

$ESPR also looking forward to the fact that in about 2 weeks we have ACC one of the largest cardiology conferences drawing about 10-15 k attendees where this will be showcased. Willing to bet that many of those cardiologists among and APP’s will be coming home after that conference and start writing BA scripts,subsequently creating a snowball effect as more people placed on the med more awareness and hence more scripts. Just a prediction but expecting sharp script growth inflection by second half of this year continuing into next year right into the lap of the triple combo …..

0 · Reply

Phasedrei Mar. 15 at 9:38 AM

$ESPR $ESPR from CHAT GPT 2. Difference in the actual prescribing effect This is where it gets interesting. USA Guidelines from the American College of Cardiology have an extremely high practical impact because: 1. Doctors rely heavily on them (for liability and quality reasons) 2. Insurance companies often cover the costs more quickly 3. Hospitals use them as the standard of care This means: Guideline → direct increase in prescribing Typical effect in the US: • Prescriptions rise sharply within 12–24 months. ⸻ Europe In Europe, the mechanism works differently. The ESC guideline from the European Society of Cardiology does influence doctors, but: the following factors are also decisive: • national reimbursement rules • budget constraints • price negotiations In Germany, for example: • G-BA benefit assessment • price negotiations with health insurance companies This means: Guideline ≠ automatic widespread

0 · Reply

Phasedrei Mar. 15 at 9:32 AM

$ESPR Chat GPT clearly explains why the Class 1A recommendation in the ACC guidelines has a significantly greater impact on prescription growth in the U.S. than the comparable recommendation from the BA in the EMA guidelines in Europe In the U.S., the legal aspect plays a major role; Doctors make themselves legally vulnerable with regard to guideline recommendations and coverage by health insurance companies/Medicare if they deny patients the optimal therapy. In Germany/Europe, with the existing principle of health insurance solidarity, guidelines are “nice to have”; but ultimately, health policy determines what constitutes reasonable costs.

0 · Reply

Albertowest Mar. 15 at 3:45 AM

$ESPR this letter contains a motion to seal, probably commercial secrets or even a settlement and it’s only for judge eyes, I think is the silver bullet against Sandoz

0 · Reply

Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 6:00 AM EDT - 5 days ago

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 3, 2026, 5:22 PM EST - 11 days ago

Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript

Mar 3, 2026, 6:00 AM EST - 12 days ago

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Feb 18, 2026, 8:00 AM EST - 25 days ago

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 26 days ago

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Feb 11, 2026, 4:30 PM EST - 4 weeks ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 14, 2026, 7:35 PM EST - 2 months ago

Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 6:00 PM EST - 2 months ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Nov 20, 2025, 4:03 PM EST - 4 months ago

Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 7:00 AM EST - 4 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 12, 2025, 10:16 AM EST - 4 months ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

CCCC CWST INSP MNDY SITM

Nov 11, 2025, 9:31 PM EST - 4 months ago

Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript

Nov 10, 2025, 7:24 AM EST - 4 months ago

Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability

Nov 6, 2025, 2:06 PM EST - 4 months ago

Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:00 AM EST - 4 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Oct 27, 2025, 8:00 AM EDT - 4 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 8, 2025, 8:01 AM EDT - 5 months ago

Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

JOBY PENG

Oct 7, 2025, 9:29 PM EDT - 5 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 5 months ago

Esperion Announces Proposed Public Offering of Common Stock

Oct 3, 2025, 8:00 AM EDT - 5 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Sep 19, 2025, 8:00 AM EDT - 6 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 7, 2025, 10:17 PM EDT - 6 months ago

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 10:39 AM EDT - 6 months ago

Top 2 Health Care Stocks That May Plunge This Month

NUVB

Aug 29, 2025, 8:00 AM EDT - 7 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 5, 2025, 10:10 AM EDT - 7 months ago

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 6:00 AM EDT - 7 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 8 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 9 months ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 14, 2025, 7:03 AM EDT - 9 months ago

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

May 12, 2025, 8:00 AM EDT - 10 months ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 11 months ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 6:30 AM EDT - 11 months ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 10:49 AM EDT - 11 months ago

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Apr 25, 2025, 8:00 AM EDT - 11 months ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 8:00 AM EDT - 11 months ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 10:34 AM EST - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

CRDF UI VOD DE FLNC GASS HII

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 8, 2024, 7:43 AM EST - 1 year ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 13, 2024, 2:08 AM EST - 1 year ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 7, 2024, 1:35 PM EST - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

Lskynrd1 Mar. 15 at 7:11 PM

$ESPR Skipper and DJ both leaving at the same time is concerning. They were both 2 of the biggest BempA supporters and both in for big money then suddenly gone during a daily sell-off, idk thoughts?

0 · Reply

GrandMasterApe Mar. 15 at 5:31 PM

$ESPR What happened to DJ? He deleted his account? Anyone know if he’s okay?

2 · Reply

Rong0722 Mar. 15 at 4:46 PM

$ESPR

0 · Reply

Albertowest Mar. 15 at 4:05 PM

$ESPR https://www.expo.acc.org/ACC26/Public/eventmap.aspx?shavailable=1&shExhlist=1 In Harlow We Trust 🫶🏻

0 · Reply

Petey3163 Mar. 15 at 12:35 PM

$ESPR do we think there will be a US partner now or with the acquisition they are definitely signaling we are going solo? Are there still any hopes of a BO?

1 · Reply

Blocktatch Mar. 15 at 11:07 AM

$ESPR What do you think of Merck's drug? Could it be a problem for Esperion in the long term? From what I understand, it could be less preferred than BA for several reasons.

1 · Reply

Moneo Mar. 15 at 10:52 AM

0 · Reply

Phasedrei Mar. 15 at 9:38 AM

0 · Reply

Phasedrei Mar. 15 at 9:32 AM

0 · Reply

Albertowest Mar. 15 at 3:45 AM

$ESPR this letter contains a motion to seal, probably commercial secrets or even a settlement and it’s only for judge eyes, I think is the silver bullet against Sandoz

0 · Reply

DP000 Mar. 15 at 2:54 AM

$ESPR AI 😎

0 · Reply

Fish2day Mar. 15 at 1:47 AM

$ESPR when does Sheldon get his options? Then we go up.

1 · Reply

augie0030 Mar. 15 at 1:27 AM

$ESPR "Additionally, subsequent to December 31, 2025, 11,250,000 warrants were exercised for $16.2 million in net proceeds, after issuance fees." - 10K Makes a lot of sense why the stock has been getting hammered this year. Fortunately seems like we are at the end of the warrants.

1 · Reply

wRsYUeX Mar. 15 at 1:21 AM

$ESPR Just imagine if Sheldung was smart and use the $ 75 million dollars he paid for Corstasis to promote NEXLIZET and NEXLETOL on mainstream media now that Guidelines have been released. I have NO doubt that promoting our existing products would yield significantly higher IRR and allow us to reach profitability much quicker.

3 · Reply

Lskynrd1 Mar. 15 at 12:54 AM

$ESPR The SP going down everyday has been difficult to deal with. This is really great news and i hope we start to go up a little now.

0 · Reply

Gary9912 Mar. 15 at 12:52 AM

$ESPR I certainly don’t want start an argument on social media with this gal, but I have to take a different stance on this,although I don’t agree with CNN too often, if there’s millions of more Americans taking statins (because they’re getting on them at an earlier age) well then 10 to 30% of them will be statin intolerant once they start taking the statins which per the new recommendations, is an easy fix, prescribe them poor folks BA. It sends a lot of business our way so I think CNN is doing a good job spreading the word. Keep up the good work. Shorts better run for cover, the party is officially over.

1 · Reply

wellington1234 Mar. 14 at 11:43 PM

$ESPR

0 · Reply

augie0030 Mar. 14 at 11:32 PM

$ESPR Does anyone know where the Ben quote is where he said Esperion will one day not be known as a cardiovascular company? Might be taking crazy pills but I think he said that.

1 · Reply

Regia Mar. 14 at 10:41 PM

$ESPR I need to clarify the earlier post I made regarding Esperion’s $1.55 warrants. After reviewing the March 2026 10‑K, the correct numbers are: Dec 31, 2025: ~18.89M warrants outstanding (not 26M as I previously stated) Early 2026 exercises (Jan–Feb): 11.25M warrants converted → cash already in Esperion’s hands (~$16.2M net) Remaining warrants: ~7.64M → potential additional cash if exercised ~ $11.8M So, the earlier calculation I posted was incorrect — I appreciate readers flagging this. The key takeaway remains bullish: most warrants have already converted, cash is in the company, and remaining potential dilution is small. Apologies for the confusion, and thanks for your patience while we corrected the record.

2 · Reply

LangL Mar. 14 at 10:35 PM

$ESPR Cashless conversion of their warrants. Armistice Capital has had the same problem as BlackRock, investors looking to cash out. So I'm sure they aren't paying cash to excercise the warrants. SP will go up when they stop exercising.

1 · Reply

LangL Mar. 14 at 10:30 PM

$ESPR

0 · Reply

DP000 Mar. 14 at 10:26 PM

$ESPR The new 2026 ACC/AHA cholesterol guidelines are starting to shine a spotlight on BA, positioning it as a standard non-statin add-on therapy. As doctors move toward earlier combination treatment instead of slow step-by-step escalation, MORE patients are being exposed to the drug SOONER, and prescription growth is already accelerating. For ESPR this creates a potential tailwind, as rising physician adoption can gradually translate into broader patient awareness and demand. Very

0 · Reply

Market Cap	626.62M
Revenue (ttm)	332.31M
Net Income (ttm)	-51.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	31.67
Profit Margin	-15.57%
Debt to Equity Ratio	-0.34

Volume	5,817,400
Avg Vol	4,949,720
Day's Range	N/A - N/A
Shares Out	256.81M
Stochastic %K	6%
Beta	1.11
Analysts	Sell
Price Target	$6.83